Dr Hope Rugo explores how new data suggest immunotherapy could reshape the standard of care for early-stage HR+ and ...
Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials Our automated approach can serve as a useful tool for ...
Lymphocyte-depleted Hodgkin’s lymphoma (LDHL) is a rare subtype of Hodgkin’s lymphoma, a cancer that develops in the lymphatic system. Hodgkin’s lymphoma (HL) is an uncommon cancer of the lymphatic ...
Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer Patients with stage IA LPHL in a single node that was completely resected were observed without further therapy; ...
Artificial intelligence (AI) can predict how well patients with rectal cancer will respond to treatment by analyzing standard ...
Trial results from DESTINY-Breast06 indicate the effectiveness of fam-trastuzumab deruxtecan-nxki in delaying disease progression for patients with hormone receptor (HR)–positive and HER2-low ...
Low dose chemotherapy involves smaller doses of medications that are given more often than the doses in traditional higher dose regimens. Learn about the advantages and effectiveness of each approach.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback